This apoptosis-inducing activity of DRE, as previously reported [9, 11] prompted further studies into its efficacy in highly aggressive colorectal cancer cells, HT-29 (p53−/−) and HCT116 (p53 WT). The gene discussed is TP53; the disease is colorectal cancer.